McCrimmon, R., Al Sifri, S., Emral, R., Mohan, V., Sauque-Reyna, L., Trescoli, C., . . . Investigators, S. T. (2021). Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.
Citación estilo ChicagoMcCrimmon, RJ, et al. Advancing Therapy With IGlarLixi Versus Premix BIAsp 30 in Basal Insulin-treated Type 2 Diabetes: Design and Baseline Characteristics of the SoliMix Randomized Controlled Trial. 2021.
Cita MLAMcCrimmon, RJ, et al. Advancing Therapy With IGlarLixi Versus Premix BIAsp 30 in Basal Insulin-treated Type 2 Diabetes: Design and Baseline Characteristics of the SoliMix Randomized Controlled Trial. 2021.
Precaución: Estas citas no son 100% exactas.